Home › Scleroderma › Kansas › Kansas City
Scleroderma clinical trials in Kansas City, KS
4 studies for Scleroderma are looking for participants at sites in and around Kansas City (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
RecruitingPhase 1
- University of Kansas Cancer Center, Kansas City
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
RecruitingPhase 1
- University of Kansas Medical Center, Kansas City
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
RecruitingPhase 2/3
- University of Kansas Medical Center, Kansas City
Platform Clinical Study for Conquering Scleroderma
RecruitingPhase 2
- University of Kansas School of Medicine, Kansas City
About Scleroderma
Scleroderma is an autoimmune disease that causes inflammation and thickening in the skin and other areas of the body. The exact cause of scleroderma is unknown.
More about Scleroderma on MedlinePlus
Scleroderma trials in other cities
- New York City, NY10 studies
- Ann Arbor, MI9 studies
- Houston, TX8 studies
- Chicago, IL8 studies
- Los Angeles, CA7 studies
- Boston, MA7 studies
- Durham, NC7 studies
- Baltimore, MD6 studies
- Dallas, TX5 studies
- New Orleans, LA5 studies
- Miami, FL5 studies
- Philadelphia, PA5 studies
Other studies in Kansas City
- Interstitial Lung Diseases13 studies
- Obesity13 studies
- Cystic Fibrosis13 studies
- Acute Myeloid Leukemia12 studies
- Prostate Cancer12 studies
- Heart Failure12 studies
- Non-Small Cell Lung Cancer12 studies
- Cardiovascular Disease12 studies
- Breast Cancer12 studies
- Lung Cancer11 studies
- Bladder Cancer10 studies
- Asthma9 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.